Insider Selling: NovoCure (NASDAQ:NVCR) Insider Sells 1,100 Shares of Stock

NovoCure Limited (NASDAQ:NVCR) insider Michal Nath Puri sold 1,100 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $13.31, for a total value of $14,641.00. Following the completion of the transaction, the insider owned 201,322 shares in the company, valued at approximately $2,679,595.82. This trade represents a 0.54% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

NovoCure Price Performance

Shares of NVCR traded up $0.81 during trading hours on Thursday, hitting $14.23. 2,315,394 shares of the stock were exchanged, compared to its average volume of 2,231,897. The stock’s 50-day moving average price is $12.73 and its two-hundred day moving average price is $12.70. NovoCure Limited has a 12-month low of $9.82 and a 12-month high of $21.55. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.50 and a current ratio of 2.90. The company has a market cap of $1.62 billion, a price-to-earnings ratio of -11.66 and a beta of 0.71.

NovoCure (NASDAQ:NVCR) last announced its earnings results on Thursday, February 26th. The medical equipment provider reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.19. The company had revenue of $174.35 million for the quarter, compared to analysts’ expectations of $174.40 million. NovoCure had a negative net margin of 20.79% and a negative return on equity of 39.11%. The firm’s quarterly revenue was up 8.2% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.61) EPS. Research analysts expect that NovoCure Limited will post -1.3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. HC Wainwright upped their price target on NovoCure from $47.00 to $49.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Evercore set a $20.00 target price on NovoCure in a report on Monday, January 5th. Wedbush reiterated a “neutral” rating and set a $18.00 price target on shares of NovoCure in a report on Thursday, January 15th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of NovoCure in a report on Thursday, January 22nd. Three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, NovoCure currently has a consensus rating of “Hold” and an average target price of $26.93.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of NVCR. Empowered Funds LLC purchased a new position in NovoCure in the 4th quarter valued at approximately $33,000. SJS Investment Consulting Inc. acquired a new stake in shares of NovoCure in the third quarter valued at $41,000. Kestra Advisory Services LLC purchased a new position in NovoCure in the fourth quarter valued at $49,000. Larson Financial Group LLC grew its stake in NovoCure by 662.1% during the 3rd quarter. Larson Financial Group LLC now owns 4,100 shares of the medical equipment provider’s stock worth $53,000 after purchasing an additional 3,562 shares in the last quarter. Finally, Headlands Technologies LLC acquired a new stake in NovoCure in the 2nd quarter valued at about $88,000. Institutional investors and hedge funds own 84.61% of the company’s stock.

NovoCure Company Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.